hrp0094p2-146 | Diabetes and insulin | ESPE2021

A Rare Clinical Case Of A Combination Of Monogenic And Autoimmune Diabetes Mellitus.

Romanenkova Elizaveta , Titovich Elena , Laptev Dmitry , Peterkova Valentina , Bezlepkina Olga ,

Introduction: Type 1 diabetes mellitus (T1D) is the most common form of carbohydrate metabolism disorder in childhood. There are also monogenic forms of diabetes. In the world literature, there are isolated mentions of the combination of monogenic and autoimmune forms of diabetes mellitus.Clinical case: A 10-year-old obese patient presented with hyperglycemia. At hospitalization: height 168 cm, weight 87 kg, SDS BMI +3.0. Glycemia 14.4 m...

hrp0094p2-270 | Growth hormone and IGFs | ESPE2021

Unified training materials to improve adherence to GH-treatment

Lundberg Elena , Renholm Petra , Molin AEsa , Ellerth Ebba , Ernstsson Camilla ,

Background: Since the 1980s, growth hormone (GH) treatment has been administered to children as daily subcutaneous (SC) injections. GH-treatment is extremely costly, and requires a high level of training and education, otherwise there is a risk of a poor response to treatment by the patient. This can lead to a waste of time and money for the family. The key to good adherence and successful treatment is patient understanding of the growth/metabolic problem and ...

hrp0097p1-245 | Diabetes and Insulin | ESPE2023

Combination of mutations in the HNF1A and ABCC8 genes: clinical polymorphism in members of the same family.

Eremina Irina , Raykina Elizaveta , Titovich Elena , Peterkova Valentina , Laptev Dmitry

Mutations in HNF1A gene underlie the development of maturity onset diabetes of the young type 3 (MODY3). Mutations in ABCC8 gene are the cause of neonatal DM and the rare MODY12, which is clinically similar to MODY3. In these forms of MODY, there is a high sensitivity to sulfonylurea. Patient A, 17 y.o. He was born to woman with gestational DM. At the age of 12.5, fasting hyperglycemia of 13 mmol/l was detected. Insulin therapy was not prescribed due to the parent’s refu...

hrp0097p2-56 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Monogenic Diabetes (MODY) in Adolescents and Personalized Treatment.

Mozzato Chiara , Meneghin Alice , Monti Elena , Trevisson Eva , Guazzarotti Laura

Pathologically elevated serum levels of fibroblast growth factor-23 (FGF23), a bone-secreted hormone that regulates phosphorus homeostasis, result in renal phosphate wasting leading to rickets or osteomalacia. Patterns leading to FGF23 excess are still unknown. Recently, FGF23 elevated rickets has been associated with epidermal nevus syndrome, designating the cutaneous skeletal hypophosphatemia syndrome (CSHS). The clinical picture is not completely defined as, to date, only a...

hrp0097p2-174 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

HIgh variability of phenotypic expression of the same genotype in X linked hypophosphatemic rickets (XLH)

Meneghin Alice , Mozzato Chiara , Monti Elena , Guazzarotti Laura

X-linked hypophosphataemia (XLH) is a dominant disorder caused by mutations in PHEX (located at Xp22.1), associated with rickets, lower limb deformities, pain, poor mineralization of the teeth and disproportionate short stature in children. The characteristics and severity of XLH vary between patients. Early diagnosis and specific treatment is usually decisive to improve short and long term patient outcomes. We describe the variability of phenotype in two sisters carrying the ...

hrp0097p2-63 | Diabetes and Insulin | ESPE2023

The importance of genetic testing and the appropriate use of glibenclamide in neonatal diabetes

Tumasyan Dalar , Bayburdyan Gayane , Hovakimyan Marina , Arakelyan Lusine , Aghajanova Elena

Introduction: Neonatal diabetes is a rare condition that can present in the first months of life. Neonatal diabetes has more than 20 genetic origins that are currently known. About 40% of these patients carry mutations in KCNJ11 and ABCC8 genes, which impair the pancreatic beta-cell K-ATP channels and can be treated with oral sulfonylureas. The purpose of this case report is to present a patient diagnosed with neonatal diabetes and the subsequent management of...

hrp0097p2-302 | Late Breaking | ESPE2023

ESPE School Sharing Knowledge for Saving Patients' Lives: Empowering Pediatric Endocrinologists in Armenia

Navasardyan Lusine , Lundberg Elena , Toumasyan Dalar , Muradyan Irina

Background: Practicing as a Pediatric Endocrinologist in Armenia means living in a middle- to low-income country with semi-closed borders associated with war and conflicts. There are therefore fewer opportunities to attend educational events or training at highly rated hospitals worldwide to improve knowledge and skills on pediatric endocrinology. In April 2023 the Endocrine Society of Pediatric Endocrinologists (ESPE) held the ESPE Caucasus & Central Asia...

hrp0097p2-316 | Late Breaking | ESPE2023

Family case of constitutional delay of puberty

Latyshev Oleg , Okminyan Goar , Kiseleva Elena , Romaykina Daria , Samsonova Lubov

Introduction: One of the strategies of searching the genetic causes of CDGP is analysing the genes responsible for hypogonadotropic hypogonadism (HH).Objective: To investigate the role of the HS6ST1 gene in development CDGP.Materials and Methods: Two patients - height and BMI SDS, bone age, genitometric parameters, basal hormones, GnRH analogue test, hCG test, olfactometry, brain-M...

hrp0095fc3.4 | Early Life and Multisystem Endocrinology | ESPE2022

A common polymorphism in the human P450 reductase gene (POR) causes defective steroid and drug metabolism due to protein instability

Rojas Velazquez Maria Natalia , Noebauer Mathias , Pandey Amit V

Cytochrome P450 oxidoreductase (POR) is the obligatory redox partner of steroid and drug-metabolizing cytochrome P450s located in the endoplasmic reticulum. Mutations in POR cause a broad range of disorders like congenital adrenal hyperplasia that may resemble bone malformations resembling Antley-Bixler syndrome. Genome sequencing studies have revealed the existence of a POR missense variant P228. We aimed to determine the detailed functional impact of POR variant P228L for it...

hrp0092fc3.3 | Multi-system Endocrine Disorders | ESPE2019

Variability in Drug Metabolizing Cytochrome P450 Activities Caused by Human Genetic Variations in NADPH Cytochrome P450 Oxidoreductase (POR)

Velazquez Maria Natalia Rojas , Parween Shaheena , Pandey Amit V

Background: A broad spectrum of human diseases, including abnormalities in steroidogenesis, are caused by mutations in the NADPH cytochrome P450 oxidoreductase (POR) (1-2). Cytochrome P450 proteins perform several reactions, including metabolism of steroids, drugs and other xenobiotics. Therefore, genetic variations in POR can impact many different metabolic pathways by changing the activities of cytochromes P450 (1). In 2004 the first human patients with defe...